Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography
On demand

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Cell and gene therapy vectors derived from lentiviruses (LVs) offer many potentially unique advantages over more conventional retroviral gene delivery systems. Considering their ability to integrate the host cell genome, LV vectors have become one of the most effective tools to transduce both dividing and non-dividing cells and to provide long-term and stable gene expression. The development pipeline of lentiviral particle-based therapies is growing and so is the need for more efficient manufacturing processes to meet the industry’s increasing demand for functional LVs as required for clinical trials. Despite all the manufacturing advances achieved over the last few decades, current processes and unit operations are still unable to reverse the significant losses of biological LV particles, making it a challenge to meet these demands.

Affinity chromatography can be used to simplify and optimize the purification process for viral vectors, which has been demonstrated by the development of affinity resins to purify AAV. For lentiviral vectors, however, one of the major challenges has been the development of a truly selective affinity ligand that can bind the viral envelope and simultaneously allow the preservation of its biological activity during the elution step. During this webinar we will present the CaptureSelect™ Lenti VSVG affinity matrix, specifically developed for the efficient purification of VSV-G pseudotyped lentivirus particles from suspension cultures.

Attend this webinar to learn more about:

  • the challenges associated with lentiviral vector purification
  • the development of an affinity resin to purify lentiviral vectors, using the CaptureSelect™ technology
  • how this new affinity resin can offer an efficient and scalable purification method in combination with gentle elution conditions to retain viral infectivity
Pim Hermans
Pim Hermans
Director of Ligand Discovery for BioProduction Group, Thermo Fisher Scientific

Pim Hermans leads the ligand discovery team at Thermo Fisher Scientific. Antibodies and affinity research have been a common theme throughout his whole career. After receiving his Bachelor degree in Biochemistry he proceeded to work at Holland Biotechnology where he carried out research on the production and purification of recombinant cytokines and monoclonal antibodies. By joining Unilever-Bestfoods, Pim was one of the first scientists involved in the early development and exploration of camelid derived single domain antibodies (VHHs). He joined the Bio Affinity Company (BAC, now part of Thermo Fisher Scientific) in 2003. As head of the Ligand Discovery Department Pim is responsible for the development of VHH based affinity ligands for applications in process – and analytical affinity chromatography. Through the introduction of new selection and screening methodologies he and his team enabled rapid development of affinity purification - and detection tools serving a broad variety of targets.

Frank Detmers
Frank Detmers
Director of Ligand Application for CaptureSelect, Thermo Fisher Scientific

In 2001, Frank Detmers received his PhD at the department of Molecular Microbiology of the University of Groningen (The Netherlands). From 2001 until 2004 he worked as a post doctoral researcher at the Department of Cell Physiology at the Nijmegen Center of Molecular Life Sciences (NCMLS, Nijmegen, The Netherlands). He joined BAC BV (Leiden, The Netherlands) in 2004 and the focus of his work is immobilization of affinity ligands on solid supports and the development of new applications of the CaptureSelect ligands. Currently, Frank is director of ligand application for CaptureSelect at ThermoFisher. His work is focusing on the development of new purification tools in the field of antibodies, therapeutic proteins, and gene and cell therapy.